Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$80.60 USD

80.60
969,063

+1.93 (2.45%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $80.59 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.

Techne (TECH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 11.31% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.

Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.

CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Techne (TECH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.

Why the Earnings Surprise Streak Could Continue for Techne (TECH)

by Zacks Equity Research

Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ALXN vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ALXN vs. TECH: Which Stock Is the Better Value Option?

Techne (TECH) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

by Zacks Equity Research

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

by Zacks Equity Research

Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

by Zacks Equity Research

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

by Zacks Equity Research

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

by Zacks Equity Research

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

by Zacks Equity Research

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

by Zacks Equity Research

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

by Zacks Equity Research

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

by Zacks Equity Research

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

Techne (TECH) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Techne (TECH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).